
Opinion|Videos|December 16, 2024
Introduction & Case 1 Presentation: mHSPC
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, introduces case 1, a 68-year-old patient with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), highlighting the clinical presentation, diagnostic workup, and treatment considerations for high-volume metastatic disease.
Advertisement
Episodes in this series

Now Playing
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































